Logo image of PCRX

PACIRA BIOSCIENCES INC (PCRX) Stock Price, Quote, News and Overview

NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD

22.43  +0.26 (+1.17%)

After market: 22.45 +0.02 (+0.09%)

PCRX Quote, Performance and Key Statistics

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (7/22/2025, 8:00:00 PM)

After market: 22.45 +0.02 (+0.09%)

22.43

+0.26 (+1.17%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High27.64
52 Week Low11.16
Market Cap1.04B
Shares46.30M
Float45.48M
Yearly DividendN/A
Dividend YieldN/A
PE6.99
Fwd PE6.6
Earnings (Next)07-28 2025-07-28/amc
IPO02-03 2011-02-03


PCRX short term performance overview.The bars show the price performance of PCRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

PCRX long term performance overview.The bars show the price performance of PCRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of PCRX is 22.43 USD. In the past month the price decreased by -9.34%. In the past year, price increased by 11.98%.

PACIRA BIOSCIENCES INC / PCRX Daily stock chart

PCRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.43 735.86B
JNJ JOHNSON & JOHNSON 16.79 404.05B
NVO NOVO-NORDISK A/S-SPONS ADR 18.2 296.73B
NVS NOVARTIS AG-SPONSORED ADR 13.2 226.17B
AZN ASTRAZENECA PLC-SPONS ADR 16.2 218.52B
MRK MERCK & CO. INC. 10.48 204.93B
PFE PFIZER INC 7.83 142.93B
SNY SANOFI-ADR 10.71 118.71B
BMY BRISTOL-MYERS SQUIBB CO 6.54 97.72B
GSK GSK PLC-SPON ADR 8.34 74.89B
ZTS ZOETIS INC 25.11 67.31B
TAK TAKEDA PHARMACEUTIC-SP ADR 63.26 45.45B

About PCRX

Company Profile

PCRX logo image Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 790 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Company Info

PACIRA BIOSCIENCES INC

2000 Sierra Point Parkway, Suite 900

Brisbane California CALIFORNIA 07054 US

CEO: David Stack

Employees: 789

PCRX Company Website

PCRX Investor Relations

Phone: 16502428052

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the stock price of PACIRA BIOSCIENCES INC today?

The current stock price of PCRX is 22.43 USD. The price increased by 1.17% in the last trading session.


What is the ticker symbol for PACIRA BIOSCIENCES INC stock?

The exchange symbol of PACIRA BIOSCIENCES INC is PCRX and it is listed on the Nasdaq exchange.


On which exchange is PCRX stock listed?

PCRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PACIRA BIOSCIENCES INC stock?

13 analysts have analysed PCRX and the average price target is 39.37 USD. This implies a price increase of 75.53% is expected in the next year compared to the current price of 22.43. Check the PACIRA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PACIRA BIOSCIENCES INC worth?

PACIRA BIOSCIENCES INC (PCRX) has a market capitalization of 1.04B USD. This makes PCRX a Small Cap stock.


How many employees does PACIRA BIOSCIENCES INC have?

PACIRA BIOSCIENCES INC (PCRX) currently has 789 employees.


What are the support and resistance levels for PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a support level at 21.59 and a resistance level at 22.44. Check the full technical report for a detailed analysis of PCRX support and resistance levels.


Is PACIRA BIOSCIENCES INC (PCRX) expected to grow?

The Revenue of PACIRA BIOSCIENCES INC (PCRX) is expected to grow by 6.01% in the next year. Check the estimates tab for more information on the PCRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PACIRA BIOSCIENCES INC (PCRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PACIRA BIOSCIENCES INC (PCRX) stock pay dividends?

PCRX does not pay a dividend.


When does PACIRA BIOSCIENCES INC (PCRX) report earnings?

PACIRA BIOSCIENCES INC (PCRX) will report earnings on 2025-07-28, after the market close.


What is the Price/Earnings (PE) ratio of PACIRA BIOSCIENCES INC (PCRX)?

The PE ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.99. This is based on the reported non-GAAP earnings per share of 3.21 and the current share price of 22.43 USD. Check the full fundamental report for a full analysis of the valuation metrics for PCRX.


What is the Short Interest ratio of PACIRA BIOSCIENCES INC (PCRX) stock?

The outstanding short interest for PACIRA BIOSCIENCES INC (PCRX) is 12.32% of its float. Check the ownership tab for more information on the PCRX short interest.


PCRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PCRX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PCRX. While PCRX has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PCRX Financial Highlights

Over the last trailing twelve months PCRX reported a non-GAAP Earnings per Share(EPS) of 3.21. The EPS increased by 6.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -5.97%
ROE -11.87%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%1.08%
EPS 1Y (TTM)6.64%
Revenue 1Y (TTM)27.59%

PCRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to PCRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -7.79% and a revenue growth 6.01% for PCRX


Ownership
Inst Owners111.44%
Ins Owners0.69%
Short Float %12.32%
Short Ratio8.2
Analysts
Analysts75.38
Price Target39.37 (75.52%)
EPS Next Y-7.79%
Revenue Next Year6.01%